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Abstract: Of the millions of HTLV-1 infected carriers worldwide, 3–5% will develop an 
aggressive T-cell neoplasm that is highly refractory to conventional therapy. The virus 
carries the Tax oncogene which constitutively activates the NFκB pathway. This co-option 
of signaling through NFκB provides for the HTLV-1 infected cell an escape from cell cycle 
arrest and apoptosis, a steady source of growth factors, and a mechanism by which the 
virus can activate its own target cell. Therapies that target the NFκB pathway sensitize 
adult  T-cell  leukemia/lymphoma  (ATLL)  cells  to  apoptosis.  A  focus  on  translational 
interrogation of NFκB inhibitors in animal models and ATLL patients is needed to advance 
NFκB-targeted ATLL therapies to the bedside.  
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1. Introduction 
Of the 15–20 million HTLV-1 infected carriers worldwide, more than 500,000 will develop an 
aggressive T-cell neoplasm that is highly refractory to conventional therapy. Despite intensive efforts 
to  improve  the  overall  survival,  adult  T-cell  leukemia/lymphoma  (ATLL)  remains  one  of  the 
hematologic  malignancies  with  the  poorest  prognosis.  ATLL  is  typically  preceded  by  decades  of 
clinical  latency  during  which  infected  cells  accumulate  selectable  traits  leading  to  malignant 
transformation. Host pathways commandeered by the virus can be used as therapeutic targets and a 
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constitutively activated NFκB pathway has emerged as an essential hit in the development of ATLL. 
Research into the mechanisms underlying HTLV-1 modulation of the NFκB pathway has revealed the 
extent to which HTLV-1 oncogenesis is dependent on the NFκB pathway [1,2]. Mouse models of 
ATLL  have  also  been  created  to  recapitulate  the  virus  induced,  NFκB-dependent  leukemias  and 
lymphomas. Translational investigations of NFκB inhibitors in mouse models and ATLL patients are 
necessary to bring this work from bench to bedside.  
2. HTLV-1 Oncogenesis Depends on NFκB 
During  decades  of  clinical  latency  HTLV-1  modulates  host  signaling  pathways  to  promote 
proliferation  of  infected  cells.  Among  the  genes  carried  in  the  viral  genome,  the  40  kDa  viral 
transcriptional transactivator (Tax) is sufficient to promote cellular transformation. The mechanism 
utilized by Tax to promote cellular transformation is multi-faceted, broadly involving activation of 
proliferation, dysregulation of cell cycle checkpoints, and promotion of genetic instability. While the 
affects of Tax expression in a cell are diverse, Tax depends on a central signaling pathway for its 
transforming activity. Mouse models in which Tax is expressed in the lymphocyte compartment have 
constitutively  active  NFκB  and  reproduce  many  aspects  of  HTLV-1  pathogenesis  (Table  1).  Tax 
expression in the absence of other viral factors is sufficient to activate the NFκB pathway and cause 
leukemia, lymphoma, solid tumors, splenomegaly, and osteolytic disease. More than 20 years ago 
Nerenberg identified a role for NFκB in tumor growth in a transgenic mouse model in which Tax, 
under the regulation of the HTLV-1 LTR, developed neurofibromas [3]. However, LTR-driven Tax 
expression in mouse models most often resulted in disorders associated with chronic inflammation, 
another NFκB-mediated process [4–7]. Other promoters were used in transgenic constructs to restrict 
Tax expression to the lymphoid compartment and better model ATLL-like malignancies. In one mouse 
model, the granzyme B promoter was used to drive Tax expression in activated T-cells and NK cells. 
These mice developed leukemia and lymphoma and tumors associated with high levels of NFκB and 
NFκB-regulated genes [8]. Tax driven by the Lck promoter also causes an ATLL-like malignancy in 
transgenic  mice  in  which  NFκB  is  constitutively  elevated  [9,10].  The  necessity  of  NFκB  in  
Tax-mediated transformation was confirmed using HTLV-1 molecular clones in which a single point 
mutation in the Tax oncogene that disrupts its ability to activate the NFκB pathway (Figure 1) also 
eliminates the virus’ ability to transform primary cells [11,12]. These data establish that constitutive 
activation of the NFκB pathway is essential in the process of Tax-mediated oncogenesis.  Viruses 2011, 3                         
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Table 1. Summary of tax transgenic mouse models of adult T-cell leukemia/lymphoma (ATLL). 
Promoter  Gene  Strain  Diseases Observed  Relevance to 
ATLL  Merits of Model  Weaknesses of 
Model 
Therapies 
Tested  Ref 
HTLV LTR 
Tax 
C57BL/
6 
X 
DBA/2 
X 
CD1 
Mesenchymal 
Tumors Thymic 
atrophy 
Not Observed 
Overexpression of 
TGF-beta, activation of 
NFκB 
Tax transforms 
fibroblasts but not 
thymocytes 
NFκB 
ODN 
[49] 
[50] 
[51] 
Neurofibromatosis 
Adrenal Tumors  Not Observed 
Tax activation of 
Nerve growth factor 
and repression of NF1 
Not associated with 
HTLV associated 
diseases in humans 
None 
[52] 
[53] 
[54] 
[55] 
Muscle degeneration  Myositis  High levels of Tax 
expression in muscle 
Incomplete 
penetrance  None  [56] 
Exocrinopathy 
Lymphadenopathy 
Splenomegaly 
Sjogren 
syndrome 
ocular lesions 
NfκB inflammatory 
disorders associated 
with Tax 
Caused by B not T 
lymphocytes  None  [57] 
[58] 
Bone Turnover  Lytic bone 
lesions 
NFkB associated bone 
lesions 
Incomplete 
penetrance  None  [59] 
Tax βgal  Mesenchymal 
Tumors  Not Observed 
Tax expression in 
response to tissue 
damage 
Tissue damage not 
correlated with 
tumor 
None  [60] 
[61] 
HTLV LTR 
pX 
C57BL/
6 X 
CD1 
Thymic Atrophy  Not Observed 
Effects of pX on 
thymus independent of 
promoter used 
pX gene expression 
not detectable  None  [62]  Ig-SV40 
MMTV 
LTR 
HTLV LTR 
pX 
C3H/ 
HeN 
Inflammatory 
Arthropathy 
Osteogenesis 
Autoimmunity 
Arthritis 
IL-1, IL-6, TNFα, 
TGFβ detected in 
joints.  
No malignancy 
Anti-Fas 
mAb  
(RK-8) 
[4] 
[5] 
[7] 
[63] 
[64] 
Tax 
CD4  Tax 
HTLV LTR  Tax  C3H  Mesenchymal 
Tumors 
NFκB 
mediated 
malignancy 
IκB degradation leads 
to constitutive NFκB 
activation  
Expression 
restricted to CNS 
and testes 
None  [65] 
Ig  Tax 
FVB/N 
Not Observed  Not Observed 
Lymphoma with CNS 
involvement 
Roles of c-Myc and 
Tax unclear   None  [66]  Ig 
HTLV LTR 
Tax  
c-myc 
CD4+ Lymphoma 
CNS Tumors 
CD4
+ 
Lymphoma 
GzmB 
Tax 
C57BL/
6 
LGL lymphoma 
Leukemia 
Osteolytic lesions 
Splenomegaly 
Lymphadenopathy 
Hypercalcemia  Lymphoma 
Leukemia 
Lytic bone 
lesions 
Hypercalcemia 
NFkB mediated 
leukemia lymphoma 
Not a CD4+ T cell 
malignancy 
Bortezomi
b 
[8] 
[36] 
Tax  
IL-2−/− 
IL-2 not required for 
phenotype 
Not a CD4+ T cell 
malignancy  None  [29] 
Tax  
IFNγ−/− 
Accelerated tumor 
onset and death 
May also affect 
tumor immunity  None  [32] 
Tax 
P53−/− 
Accelerated disease 
progression 
Only seen in 
P53+/− mice  None  [22] 
GzmB 
ApoE 
Tax 
OPG 
Reduced cancer and 
bone lesions 
Causes 
osteopetrosis 
Zoledronic 
Acid  [27] 
GzmB 
HTLV LTR 
Tax 
LUC  C57BL/
6 
X 
FVB 
Bioluminescent tumors  Not a CD4+ T cell 
malignancy  None  [31] 
GzmB 
HTLV LTR 
Tax  
LUC 
ARF−/− 
Lymphoma 
Bone Turnover 
Osteosarcoma 
ARF−/− is not 
equivalent to p53−/− 
Osteosarcoma not 
associated with 
ATLL 
Zoledronic  
Acid  [67] 
GzmB 
HTLV LTR 
TCR 
Tax 
LUC 
TCR
ova 
C57BL/
6 
X 
FVB 
X 
BALB/c 
Leukemia 
Lymphoma 
Lymphadenopathy 
Tax induced by 
wounding and T cell 
activation leads to 
enhanced 
tumorigenesis 
Primary malignancy 
not a not a CD4+ T 
cell malignancy 
None  [35] 
EμSRα 
TET 
TET 
tTA 
Tax 
M47 
FVB/N 
Alopecia 
Hyperkeratosis 
Splenomegaly 
Skin Lesions 
Tet-inducible model 
allows repression of 
Tax  
No malignancy  None  [68] 
EμSRα 
TET 
tTA 
M22  Not observed  Not Observed 
Control establishes 
role of NFκB in 
disease 
Lck-prox  Tax  C57BL/
6 
CD4- CD25+ pre-T 
cell Leukemia 
Lymphoma 
Leukemia 
Lymphoma 
Cancer stem cells 
derived from these 
mice recapitulate 
disease in SCID 
Not a CD4+ T cell 
malignancy 
As2O3 + 
IFN-α 
AMD3100 
[9] 
[69] 
[70] 
[71] 
Lck-dis  Tax 
C57BL/
6 
X 
DBA/2 
CD4+ CD25- mature 
T cell leukemia 
lymphoma 
Arthritis 
Leukemia 
Lymphoma 
Mature CD4+ or CD8+ 
T cell malignancy  Cells lack CD25  None  [72] 
[73] 
CD3-ε  Tax 
C57BL/
6 
X 
CBA 
Mesencymal tumors 
Mammary Adenoma  Not Observed  Tax associated with 
apoptosis and p53 
Not a CD4+ T cell 
malignancy  None  [74] Viruses 2011, 3                         
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Figure  1.  Tax  activation  of  NFκB  is  required  for  immortalization.  The  creation  of  a 
molecular clone of HTLV-1 by Kimata et al. [11] enabled the analysis of Tax mutants for 
immortalization  determinants  [12].  Mutations  that  inhibit  Tax  activation  of  the  NFκB 
pathway  prevented  immortalization  of  peripheral  blood  mononuclear  cells  (PBMC), 
whereas  mutations  that  inhibit  Tax  activation  of  the  CREB  pathway  allowed  NFκB 
activation and Tax-mediated immortalization. 
 
3. The NFκB Signaling Pathway 
The NFκB family of transcription activators are involved in many biological processes including 
cell survival, stress responses, and development [13]. NFκB is also a central regulator of immune 
effectors  including  cytokine  and  chemokine  secretion,  receptor  expression,  antigen  presentation, 
cellular proliferation, and programmed cell death. The NFκB family contains five members (RelA, 
RelB, cRel, p50, and p52) that can form 15 different homo or heterodimers with a variety of activities 
and tissue specificities. Latent or unstimulated cells retain NFκB proteins in the cytoplasm bound to 
various  inhibitors  of  kappa  B  (IκB)  proteins.  Upon  activation,  IκB  kinases  (IKKs)  release  NFκB 
complexes which then translocate to the nucleus through two distinct pathways, termed canonical and 
non-canonical. These arms are distinct but retain extensive mechanisms of cross-regulation [13]. The 
canonical pathway, which is activated by pro-inflammatory signals, is IKKγ dependent, while the  
non-canonical pathway functions independent of IKKγ, instead depending on NFκB inducing kinase 
(NIK). The non-canonical pathway is activated in response to tumor necrosis factor (TNF) receptors 
during  lymphoid  development.  It  is  because  NFκB  proteins  regulate  these  myriad  pathways  that 
cancers  and  viral  pathogens  exploit  NFκB  to  enhance  proliferation,  cell  survival,  and  evasion  of 
immune responses (Figure 2). Consequently, this array of human cancers could also all be targeted by 
NFκB directed therapies.  
4. Tax Targets the NFκB Pathway 
Lymphoma is commonly associated with constitutive NFκB activity and oncogenic human viruses, 
including  Epstein-Barr virus  (EBV), Human  papillomavirus (HPV),  Hepatitis  B virus (HBV),  and 
Hepatitis C virus (HCV) all carry viral factors that directly target and co-opt the NFκB pathway during 
gag pol env pX LTR LTR
TAX
M22
M47
Immortalization PBMC
HTLV-1 
Molecular 
Clone
NFkB
NFkB
CREB
CREBViruses 2011, 3                         
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oncogenesis. HTLV-1 uses Tax in multiple strategies to efficiently activate both the canonical and 
non-canonical NFκB pathways (Figure 2).  
Figure  2.  Tax  targets  the  NFκB  pathway.  A  simplified  schematic  of  NFκB  signaling 
pathways  highlighting  regulatory  proteins  commonly  targeted  by  viruses  [1,2,13].  
HTLV-1  Tax  targets  the  pathway  at  several  points.  (a)  Tax  leads  to  the  activation  of  
receptor-associated kinases that signal through the NFκB pathway [16,17]. (b) Tax directly 
binds to IKKγ (NEMO) which leads to constitutive phosphorylation and degradation of the 
NFκB  repressor  IκB  [15].  (c)  Tax  activates  and  recruits  IKKα  to  p100  stimulating 
phosphorylation, ubiquitination, and processing to p52 leading to nuclear translocation [19]. 
(d) Tax alters binding or recognition of a variety of transcription factors and DNA binding 
proteins increasing the number of genes regulated by the NFκB pathway [18]. 
 
 
Tax directly interacts with several NFκB members, including RelA, p50, p52, IKKγ, and the NFκB 
precursor protein p100 such that both arms of the NFκB pathway are involved in tumorigenesis [1,14]. 
Rapid and reversible, the canonical pathway of NFκB is transient and strictly regulated. Tax activates 
the canonical pathway through a variety of mechanisms including binding to IKKγ, activating the Akt 
pathway  which  signals  through  IKKα,  or  by  promoting  phosphorylaton  of  p65  via  activation  of  
pro-inflammatory cytokines [15–18]. HTLV-1 uses the canonical pathway, through Bcl-xl, to prevent 
intrinsic apoptosis [20]. The non-canonical arm of NFκB, which involves new protein synthesis of 
p100 and RelB downstream of NIK, is slower and irreversible. Tax-induced p100 processing or its 
physical interaction with Tax in the nucleus contribute to Tax activation of the non-canonical NFκB 
pathway as well. The non-canonical pathway has a broader anti-apoptotic effect on both apoptotic 
pathways  through  BCL-XL,  FLIP,  XIAP,  and  CIAP,  making  it  a  more  powerful  therapeutic  
β
Y
α
p p
IkB
p50
RelA
p100
RelB
p50
RelA
p52
RelB
nucleus
cytoplasm
HBV e Ag
HPV E5
HIV Env
HTLV Taxa
HTLV Taxb
HCV core
EBV LMP-1
HCV NS1
HTLV Taxc
HBVx Ag
HTLV Taxd
SV40 small T
HPV E6
Receptor
complex
IKK 
complex
Canonical Non-Canonical
Cytoplasmic
NFkB
complex
Nuclear
NFkB
complex
B cell Receptor
T cell receptor
Toll-like Receptors
Growth factor Receptors
Lymphotoxin βReceptor
Virus Target
Viruses that cause inflammation-associated cancers 
target the NFκB pathway
a: Tax leads to the activation of receptor associated kinases that signal through the NFκB 
pathway.
b: Tax directly binds to IKKγ (NEMO) which leads to constitutive phosphorylation and 
degradation of the NFκB repressor IκB.  
c: Tax activates and recruits IKKα to p100 stimulating phosphorylation, ubiquitination, and 
processing to p52 leading to nuclear translocation. 
d: Tax alters binding or recognition of a variety of transcription factors and DNA binding 
proteins increasing the number of genes regulated by the NFκB pathway   Viruses 2011, 3                         
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target [20]. In fact, the difference in transforming potential between HTLV-1 and HTLV-2 has been 
linked to the ability of HTLV-1 Tax to activate the non-canonical arm of the NFκB pathway [21]. 
5. NFκB and Apoptosis 
Constitutive  activation  of  NFκB  family  members  and  downstream  effectors  provides  several 
selective  advantages  to  malignant  cells.  One  selective  advantage  offered  by  unregulated  NFκB 
signaling is the ability to bypass checkpoint controls and p53-mediated apoptosis. In transformed cell 
lines as well as freshly isolated ATLL samples, NFκB activation supports the survival and proliferation 
of  HTLV-1  infected  cells. Moreover, lymphoma  cell  lines  with  constitutively  activated  NFκB  are 
resistant  to  a  variety  of  inducers  of  apoptosis  including  gamma-irradiation,  etoposide,  and 
combinations of cycloheximide and TNF or TRAIL, and resist the activation of both the intrinsic and 
extrinsic apoptotic pathways [20]. Like ATLL cells, malignant cells arising in mouse models are also 
resistant  to  chemotherapy  and  radiation-induced  apoptosis  [22].  Although  mutations  deleting  or 
inactivating  p53  are  common  in  ATLL,  Tax  is  capable  of  bypassing  p53-dependent  cell-cycle 
checkpoints  through constitutive  activation  of  the  NFκB  pathway  [22].  Tax  is  known  to  suppress  
a  wide  range  of  pro-apoptotic  factors  and  stimulate  expression  of  factors  acting  as  apoptosis  
inhibitors  [14].  The  necessity  of  NFκB  in  Tax-mediated  resistance  to  apoptosis  is  revealed  when 
overexpression of IκB or loss of p65 represses the NFκB pathway, and re-sensitizes Tax-transformed 
cells to inducers of p53-mediated apoptosis [23]. 
6. NFκB and Inflammation 
HTLV-1 in humans is also associated with chronic inflammation which is mediated by NFκB. 
Chronic inflammation resulting from Tax-mediated canonical NFκB activity leads to HAM/TSP in 
some HTLV-1 carriers [24], but may also contribute to development of ATLL. Chronic inflammation 
promotes  cancer  through  complex  mechanisms  involving  cytokine  mediated  proliferation,  stromal 
activation,  immune  modulation,  and  release  of  DNA  damage  promoting  agents  [25,26].  Genes 
activated by Tax in transgenic mice are directly or indirectly regulated by NFκB inducible cytokines 
that  promote inflammation  and  immune  cell  infiltration  (Figure  3). Tax tumor  cells express IL-6,  
M-CSF, IL-1, TNF-α, and Tax expression enhances IL-6 and TNF-α expression in vitro and in vivo 
[27,28].  Moreover,  malignant  cells  express  NFκB  inducible  cytokines  and  stimulate  cytokine 
production  in  tumor  infiltrating  cells  and  stroma.  Factors  produced  by  Tax-tumor  cells  cause 
splenomegaly, neutrophilia, elevated white count and anemia in transgenic mice and SCID recipients 
of tumor allografts [27,29]. Preceding tumorigenesis in transgenic mice, Tax and the NFκB pathway 
promote a state of chronic inflammation in which Tax-induced malignancies can thrive [30].  Viruses 2011, 3                         
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Figure  3. Tax transgenic mice model ATLL. Several Tax transgenic mouse models of 
ATLL  have  demonstrated  the  sufficiency  of  Tax  as  an  independent  oncogene.  Second 
generation  strains,  such  as  the  one  depicted,  have  added  capabilities,  which  enable  
non-invasive  interrogation  of  various  Tax  activities  using  bioluminescence  imaging 
[30,31,35].  
 
 
This inflammation-associated malignancy is Tax-dependent and promoter-dependent since SV40 
large  T  under  the  same  promoter  does  not  reproduce  the  inflammation  promoting  nature  of  Tax  
tumors [29,31]. Interestingly, chronic inflammation is a complicating factor because it carries both  
tumor-promoting  and  tumor-repressing  effects.  IFNγ,  an  NFκB  inducible  gene  found  in  chronic 
inflammation,  causes  inhibition  of  tumor  angiogenesis  and  represses  tumor  growth  [32].  The 
mechanism by which Tax promotes inflammation and tumorigenesis is coupled by its regulation of the 
NFκB pathway.  
TAX-LUC
Leukemia
Lymphoma Osteolytic Lesions Activation of NFκB
Dynamic Tax Activity 
Non-invasive Imaging of Tax-Induced Tumors
GzmB-Tax Cell lines Inflammation
Luminol-BLI
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7. NFκB and T-Cells 
HTLV-1 infects and transforms CD4
+ T-cells. The NFκB pathway is essential for T-cell functions 
including T-cell development, activation, gene expression, cell cycle progression, survival, cytokine 
production, and apoptosis [13]. While Tax activates NFκB in T-cells, most freshly isolated ATLL cells 
do not express detectable levels of Tax [33]. This has been explained by the discovery that Tax is a 
primary target of cytotoxic T lymphocyte (CTL) attack, and HTLV-1 infected T-cells that express high 
levels of Tax are destroyed [34]. Is ATLL Tax-independent at the time of clinical presentation? A 
mouse model in which Tax drives expression of firefly-luciferase, allowed non-invasive, real-time 
detection of Tax activity using bioluminescence imaging (Figure 3). This model revealed that Tax 
activity, which was normally undetectable, was occasionally punctuated by short bursts of intense 
expression.  Moreover,  these  stochastic  bursts  of  Tax  expression  preceded  advancing  stages  of 
tumorigenesis  [31].  In  addition,  a  triple-transgenic  mouse  strain  carrying  an  ovalbumin-inducible  
T-cell  receptor  (TCR)  transgene  demonstrated  that  systemic  T-cell  activation  accelerated  the 
development  of  Tax-induced  lymphoma  [35].  Determining  whether  ATLL  ever  attains  Tax 
independence  awaits  an  inducible-Tax  mouse  in  which  Tax  expression  can  be  repressed  late  in 
malignancy. Importantly, in ATLL cells the NFκB pathway remains activated when Tax expression is 
repressed. Thus NFκB remains a therapeutic target even when Tax is not expressed. 
8. Targeting NFκB in vivo  
NFκB regulates the expression of a wide variety of genes implicated in proliferation, angiogenesis, 
invasion, and metastasis and the dependence of HTLV-1 oncogenesis on the NFκB pathway makes it 
an  ideal  target  for  therapeutic  attack.  Repression  of  the  NFκB  pathway  could  make  ATLL  cells 
sensitive to apoptosis, slow their proliferation, or repress aspects of the immune response that promote 
malignancy. In tissue culture and mouse models, non-specific inhibitors of the NFκB pathway like 
sodium salicylate or cyclopentenone prostaglandins can increase the sensitivity of Tax-tumor cells to 
apoptosis and repress NFκB-inducible cytokines IL-6, IL-10, IL-15, and IFN-γ [28]. Bortezomib is 
another non-specific inhibitor of the NFκB pathway that is capable of inhibiting proliferation of Tax 
tumors cells ex vivo and sensitizing cells to apoptosis [36]. Bortezomib treatment slowed tumor growth 
in  an  allograft  model  by  increasing  apoptosis,  but  toxicity  constraints  limited  the  efficacy  of  the 
treatment [36]. Bay11-7082, an IKK inhibitor, inhibits the NFκB pathway in ATLL cells and sensitizes 
HTLV-1 infected cells lines as well as primary ATLL cells to apoptosis [37]. Over the past six years 
several  additional  studies  have  therapeutically  targeted  the  NFκB  pathway  in  order  to  kill  ATLL  
cells [38]. Oridonin, NIK-333, curcumin, fucoidan, histone-deacetylase inhibitors, and a derivative of 
epoxyquinomicin C have all been reported to induce apoptosis in ATLL cells by repressing the NFκB 
pathway [39–44]. These findings serve as sufficient proof of principle that NFκB-targeted therapies 
show great promise against ATLL. The field now awaits successful clinical trials in vivo. Viruses 2011, 3                         
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9. Targeting NFκB in ATLL Patients 
The majority of ATLL patients present with acute or lymphomatous ATLL, which results in a 
median survival of 0.5–2.0 years, despite intensive chemotherapy treatment [45,46]. To determine if 
NFκB blockade is tolerated in these patients, and whether or not it improves response rates and overall 
survival, our current multicenter trial combines infusional chemotherapy (EPOCH) with bortezomib 
(Figure 4). In addition, this clinical trial includes treatment with integrase inhibitor raltegravir, which 
was found to inhibit HTLV-1 integration in tissue culture [47]. The addition of an antiviral agent to 
this ATLL treatment regimen is based on our previous clinical trial in which chemotherapy was found 
to markedly enhance virus expression in a subset of patients [48].  
Figure 4. Schema for an ATLL clinical trial using NFκB targeted therapy. The clinical  
trial  shown  has  been  approved  and  is  currently  accepting  patients.  Clinical  trials  of  
NFκB-targeted combination chemotherapies are now beginning to apply the information 
obtained from primary research to clinical practice.  
 
10. Conclusions 
Host pathways can be used as chemotherapeutic targets when they confer an essential trait to the 
cancer cell. A constitutively activated NFκB pathway represents such a target in the case of HTLV-1 
mediated ATLL. The NFκB pathway provides an escape from cell cycle arrest and apoptosis, a steady 
source  of  growth  factors,  and  a  mechanism  by  which  the  virus  can  activate  its  own  target  cell. 
Accumulating evidence supports the concept that NFκB targeted therapies sensitize ATLL cells to 
apoptosis.  Research  in  ATLL  therapies  should  now  focus  on  translational  interrogation  of  NFκB 
inhibitors in animal models and ATLL patients.  
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